Posted by Michael Wonder on 12 Aug 2021
FDA approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) combination for first-line treatment of adult patients with advanced renal cell carcinoma
11 August 2021 - Keytruda plus Lenvima is now approved for two types of cancer, including advanced renal cell carcinoma.
Merck and Eisai today announced that the U.S. FDA has approved the combination of Keytruda plus Lenvima for the first-line treatment of adult patients with advanced renal cell carcinoma.
